AGN:CSE; AGNPF:OTCQB; AGW:FSE

Algernon Pharmaceuticals Inc.

Algernon is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for its lead drug NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

AGN:CSE AGNPF:OTCQB AGW:FSE

View Company News

Visit Company Website

Expert Comments:

André Uddin, Research Capital Corporation

(8/4/21)

Algernon Pharmaceuticals Inc. has decided to terminate the development of Ifenprodil for COVID-19. . .we agree with management that the risk-benefit profile of the COVID-19 program does not justify its continuation; we view the company's move as wise. . .Algernon is switching focus to the idiopathic pulmonary fibrosis/chronic cough indication."

Pharma Company Working to Unlock Psychedelic Drug's Potential for Stroke Recovery
(7/9/21)

Algernon Pharmaceuticals CEO Christopher J. Moreau and Dr. David Nutt, the company's research stroke consultant, discuss Algernon's upcoming Phase 1 study of DMT for stroke.

Diverse Pipeline for Repurposing Drug Company Includes Treatments for Idiopathic Pulmonary Fibrosis and Chronic Cough, Pancreatic Cancer and Stroke
(6/30/21)

Repurposing extends a drug's reach and value, and Algernon Pharmaceuticals' strategy of finding and demonstrating new uses for existing drugs reduces risk, accelerates time to market and increases capital efficiency.

Drug Repurposing Firm Launches Clinical Research Program in Pancreatic Cancer
(6/3/21)

Based on various positive preclinical and clinical studies, Algernon Pharmaceuticals is pursuing Ifenprodil as a potential treatment for pancreatic tumors.

Sam Riches, Weekend Dispensary

(5/22/21)

"Algernon Pharmaceuticals Inc. says it received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its planned Phase 1 clinical trial, which is set to begin later this year with the U.K.-based Hammersmith Medicines Research. . .Algernon believes its approach could potentially lead to a breakthrough therapy designation from the FDA, which enables priority review and can fast track the clinical trial process."

Pharma Developer Finds Ifenprodil Reduces Interleukin 6 in Phase 2b/3 COVID Trial
(5/13/21)

Algernon Pharmaceuticals reported that Ifenprodil was shown to reduce interleukin 6 in its Phase 2b/3 COVID-19 Study, which the company states may have positive implications for its use in its ongoing Phase 2 trial of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough.

André Uddin, Research Capital Corporation

(5/10/21)

"Algernon Pharmaceuticals Inc. has recently filed an end-of-Phase 2 meeting request with the U.S. Food and Drug Administration to discuss advancing ifenprodil to the Phase 3 part of the Phase 2b/3 trial in COVID-19. . .ifenprodil is in a Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough, for which results are expected in H2/21. DMT, a repurposed psychedelic compound, is expected to enter into a Phase 1 trial in stroke in H2/21."

Pharmaceutical Development Company Added to First Psychedelic Stock Index ETF
(3/30/21)

Being included in the Horizons Psychedelic Stock Index Exchange Traded Fund will afford Algernon Pharmaceuticals greater investor exposure.

The Covid-19 Issue Too Many Are Ready to Overlook, and the Investing Opportunity It Creates
(3/22/21)

Have we forgotten about good Covid 19 Therapeutics? KSS MD PhD, editor-in-chief of PubBio.co, discusses three gems investors should know about.

André Uddin, Research Capital Corporation

(3/1/21)

"The database of the Phase 2b part of Algernon Pharmaceuticals Inc.'s Phase 2b/3 trial with ifenprodil in COVID-19 is to be locked for analysis on March 5, 2021; final results are expected to be disclosed shortly thereafter. Results of a Phase 2a trial with ifenprodil in idiopathic pulmonary fibrosis/chronic cough are expected in Q2/21 or Q3/21 for early chronic cough data and Q4/21 for full study data."

André Uddin, Research Capital Corporation

(2/2/21)

"Algernon Pharmaceuticals Inc. has established a program to repurpose a psychedelic compound, DMT, for stroke. . .the company is to continue a number of preclinical studies with DMT for stroke and is looking to file an investigational new drug application with the U.S. Food and Drug Administration based on DMT's historical data of Phase 1 clinical trials and new preclinical data generated by Algernon."

Clive Maund, CliveMaund.com

(2/1/21)

"Algernon Pharmaceuticals Inc. is looking like a Buy again here as it is at the bottom of the shallow uptrend that has developed from the December low, and a stop may be placed beneath the lower rail of the channel. An additional reason for buying the company here that may lead to a bigger move is the good news out of it this morning that it is commencing clinical research with a psychedelic drug for stroke treatment."

More Expert Comments

Clive Maund, CliveMaund.com (12/28/20) "The good news with Algernon Pharmaceuticals Inc. is that the stock has now arrived at a much stronger long-term support level in a deeply oversold state, so the least we can expect is a significant bounce from here. On Thursday there was a moderately bullish candle on strong volume with it closing well off the lows, which suggests that it may be reversing here or at least have hit bottom."

	André Uddin, Research Capital Corporation (12/15/20) "Algernon Pharmaceuticals Inc. reports interim results of a COVID-19 Phase 2b/3 trial with Ifenprodil. . .The results showed two positive early trends in high-dose ifenprodil at Day 15: (i) fewer patients required mechanical ventilation and (ii) the reduction of the NEWS score (used to monitor patient status) was quicker, which could potentially translate to a faster recovery down the road. . .We are maintaining our SPECULATIVE BUY rating and TP of $0.80/share. AGN remains a high risk high reward investment opportunity."

Clive Maund, CliveMaund.com (12/8/20) "Algernon Pharmaceuticals Inc. is now in a vigorous uptrend. It has paused for a rest in recent days with a small bull Pennant believed to be forming. Current light volume and strong Accumulation line suggest that another upleg is imminent."

All Penny Stocks (8/24/20) "What a spectacular run junior biotech Algernon Pharmaceuticals Inc. has made since late-November. The stock run-up is largely predicated on one virus, COVID-19. With a brief pullback over the last few months, we think it is time to revisit this stock as the technical stars may be aligning for one more major push higher."

	André Uddin, Research Capital Corporation (8/19/20) "We are initiating coverage of Algernon Pharmaceuticals Inc. with a Speculative Buy recommendation and a target price of $0.80/share. . .Algernon is focused on developing repurposed small molecules for new disease indications – these drug candidates have been already approved in ROW markets (but not approved in the U.S. or Europe). . .Algernon's lead product, ifenprodil (a marketed drug in Japan for circulatory disorders) is being repurposed for COVID-19, idiopathic pulmonary fibrosis (IPF) and chronic cough."

Baystreet (8/12/20) "Algernon Pharmaceuticals Inc. is betting that this quiet and unassuming safe generic drug, Ifenprodil, may soon become a global blockbuster. . .the company recently announced the first patient has been enrolled in its multinational human Phase 2b/3 COVID trial of Ifenprodil. . .Phase 2b data are expected before 2020E."

Experts Following This Company

Dr. KSS, Founder and Editor-in-Chief – BioPub.co
Clive Maund – CliveMaund.com
	André Uddin – Research Capital Corporation

Company News

9/9/2021 – Algernon Pharmaceuticals Announces Appointment of Harry Bloomfield, QC. as a New Board Director and Chairman

9/7/2021 – Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose

8/11/2021 – Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program and Appoints Dr. William North as Lead Consultant

8/9/2021 – Algernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College

7/7/2021 – Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

7/6/2021 – Algernon Pharmaceuticals Announces it Will Not Advance Ifenprodil into Phase 3 Trial for COVID-19

6/17/2021 – Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights

	Advancing new drug treatments for billion dollar global disease markets.
	Conducting multiple phase II clinical trials
	Experienced management team & globally recognized medical advisory board

catalyst Calendar

Q2 2021	U,S, FDA End-of-Phase 2 COVID-19 Study Meeting, Q2, 2021
Q4 2021	Phase 2 trial for IPF and chronic cough data expected Q4, 2021.
Q4 2021	Phase 1 Study planned for DMT, Q4 2021

Algernon Pharmaceuticals Inc. Content

Fact Sheet March 2021

Fact Sheet April 2020

Could the ‘spirit molecule’ be a treatment option for stroke? Weekend Dispensary By Sam Riches

Algernon Pharmaceuticals Inc.

Expert Comments:

André Uddin, Research Capital Corporation

Pharma Company Working to Unlock Psychedelic Drug's Potential for Stroke Recovery (7/9/21)

Diverse Pipeline for Repurposing Drug Company Includes Treatments for Idiopathic Pulmonary Fibrosis and Chronic Cough, Pancreatic Cancer and Stroke (6/30/21)

Drug Repurposing Firm Launches Clinical Research Program in Pancreatic Cancer (6/3/21)

Sam Riches, Weekend Dispensary

Pharma Developer Finds Ifenprodil Reduces Interleukin 6 in Phase 2b/3 COVID Trial (5/13/21)

André Uddin, Research Capital Corporation

Pharmaceutical Development Company Added to First Psychedelic Stock Index ETF (3/30/21)

The Covid-19 Issue Too Many Are Ready to Overlook, and the Investing Opportunity It Creates (3/22/21)

André Uddin, Research Capital Corporation

André Uddin, Research Capital Corporation

Clive Maund, CliveMaund.com

More Expert Comments

Clive Maund, CliveMaund.com

André Uddin, Research Capital Corporation

Clive Maund, CliveMaund.com

All Penny Stocks

André Uddin, Research Capital Corporation

Baystreet

Experts Following This Company

Company News

Pharma Company Working to Unlock Psychedelic Drug's Potential for Stroke Recovery
(7/9/21)

Diverse Pipeline for Repurposing Drug Company Includes Treatments for Idiopathic Pulmonary Fibrosis and Chronic Cough, Pancreatic Cancer and Stroke
(6/30/21)

Drug Repurposing Firm Launches Clinical Research Program in Pancreatic Cancer
(6/3/21)

Pharma Developer Finds Ifenprodil Reduces Interleukin 6 in Phase 2b/3 COVID Trial
(5/13/21)

Pharmaceutical Development Company Added to First Psychedelic Stock Index ETF
(3/30/21)

The Covid-19 Issue Too Many Are Ready to Overlook, and the Investing Opportunity It Creates
(3/22/21)